For a patient with triple-class-refractory myeloma and cytopenias who has been collected for CAR-T, would you choose aggressive chemotherapy or a bispecific antibody for bridging?

The median time to response for bispecific antibodies targeting BCMA and GPRC5d is over a month. Usually, when we employ bridging therapy we want a much quicker response. Resistance likely doesn’t play a role here because of the short time that they are being used.
I prefer to avoid VD-pace-like reg...

It is a common question and also remains a challenging situation in the real world! Many key points need to be addressed here regarding the disease (assuming pt is fit since he is undergoing CAR-T):

1. If the disease is aggressive with a high burden (I will be aggressive with using VDPACE or VDPACE-l...